MSB 1.10% 91.5¢ mesoblast limited

Ann: COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT, page-34

  1. 7,568 Posts.
    lightbulb Created with Sketch. 6834
    Bee Gee's "stayin' Alive" song would come to mind, were it not all so sad.

    90 day survival rates in a PRE-DETERMINED SUB-GROUP (that one was falsely argued for so long) showing these mortality improvements are longer-term. What a criminal shame Remestemcel-L is not out there halving mortality rates in critically ill C-19 ARDS patients (the majority of C-19 deaths) because of an all mighty cock up by the DSMB and NIH in MSB's C-19 ARDS trial - when you have a quickly changing disease cohort on of the DSMB's jobs is to redefine the trial parameters accordingly.

    Oh the humanity.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.